Paper7779709
In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
Klumper E and 5 others. Br J Cancer, 1995. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. Papers, record 7779709. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7779709
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibiotics, Antineoplastic | Major topic |
| Bone Marrow | Major topic |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | Major topic |
| Aclarubicin | |
| Child | |
| Daunorubicin | |
| Dose-Response Relationship, Drug | |
| Drug Resistance | |
| Humans | |
| Idarubicin | |
| Mitoxantrone | |
| Recurrence |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6952961 | Phase I trial of aclacinomycin A. | Cancer Treat Rep | 1982 | https://conductscience.org/library/papers/6952961 | PubMed |
| 2 | 1678081 | Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. | Lancet | 1991 | https://conductscience.org/library/papers/1678081 | PubMed |
| 3 | 3858013 | Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/3858013 | PubMed |
| 4 | 4019122 | Mitoxantrone in refractory acute leukemia in children: a phase I study. | Invest New Drugs | 1985 | https://conductscience.org/library/papers/4019122 | PubMed |
| 5 | 3516918 | Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. | Invest New Drugs | 1986 | https://conductscience.org/library/papers/3516918 | PubMed |
| 6 | 3718817 | 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures. | Br J Cancer | 1986 | https://conductscience.org/library/papers/3718817 | PubMed |
| 7 | 3757156 | Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3757156 | PubMed |
| 8 | 3471321 | Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. | Cancer Res | 1987 | https://conductscience.org/library/papers/3471321 | PubMed |
| 9 | 3476202 | Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia. | Cancer Treat Rep | 1987 | https://conductscience.org/library/papers/3476202 | PubMed |
| 10 | 3305216 | Aggressive combination chemotherapy of bone marrow relapse in childhood acute lymphoblastic leukemia containing aclacinomycin-A: a multicentric trial. | Haematol Blood Transfus | 1987 | https://conductscience.org/library/papers/3305216 | PubMed |
| 11 | 3480081 | Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3480081 | PubMed |
| 12 | 3165708 | Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. | Cancer Res | 1988 | https://conductscience.org/library/papers/3165708 | PubMed |
| 13 | 3207599 | Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line. | Br J Cancer | 1988 | https://conductscience.org/library/papers/3207599 | PubMed |
| 14 | 3062256 | [Antineoplastic effectiveness and toxicity of idarubicin (4-demethoxy-daunorubicin) in recurrent acute leukemias in childhood]. | Klin Padiatr | 1988 | https://conductscience.org/library/papers/3062256 | PubMed |
| 15 | 2924371 | Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2924371 | PubMed |
| 16 | 2547527 | Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2547527 | PubMed |
| 17 | 2576650 | Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia. | Eur J Cancer Clin Oncol | 1989 | https://conductscience.org/library/papers/2576650 | PubMed |
| 18 | 2208112 | Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. | Cancer Res | 1990 | https://conductscience.org/library/papers/2208112 | PubMed |
| 19 | 2257305 | In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. | Blood | 1990 | https://conductscience.org/library/papers/2257305 | PubMed |
| 20 | 1878583 | Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. | Blood | 1991 | https://conductscience.org/library/papers/1878583 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41310667 | Targeting the MAGED2-TRIM28-FLNC axis overcomes chemoresistance in TNBC via EMT suppression. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/41310667 | PubMed |
| 27632202 | Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy. | PLoS One | 2016 | https://conductscience.org/library/papers/27632202 | PubMed |
| 25295084 | Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin's lymphoma patients with a poor performance status or comorbidity. | Oncol Lett | 2014 | https://conductscience.org/library/papers/25295084 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7779709
GET https://conductscience.org/api/papers/v1/7779709/references?page=2